Get the Stockscreener App
9.96
4.32%
-0.45
Pre-market:
9.85
-0.11
-1.10%
Atara Biotherapeutics Inc stock is traded at $9.96, with a volume of 80,631.
It is down -4.32% in the last 24 hours and up +3.97% over the past month.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA3431, and ATA3219.
See More
Previous Close:
$10.41
Open:
$10.5
24h Volume:
80,631
Relative Volume:
0.06
Market Cap:
$89.74M
Revenue:
$23.14M
Net Income/Loss:
$-9.47M
P/E Ratio:
-11.28
EPS:
-0.8827
Net Cash Flow:
$-25.88M
1W Performance:
+3.97%
1M Performance:
+3.97%
6M Performance:
-44.51%
1Y Performance:
+12.93%
1-Day Range:
$9.85
$10.92
1-Week Range:
$9.42
$10.99
52-Week Range:
$3.92
$19.14
Atara Biotherapeutics Inc Stock (ATRA) Company Profile
Name
Atara Biotherapeutics Inc
Sector
Industry
Phone
805-623-4211
Address
1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA
Compare ATRA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATRA
Atara Biotherapeutics Inc
|
9.96 | 89.74M | 23.14M | -9.47M | -25.88M | -0.8827 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Atara Biotherapeutics Inc Stock (ATRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-13-26 | Downgrade | Canaccord Genuity | Buy → Hold |
| Nov-09-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-09-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-09-23 | Downgrade | Mizuho | Buy → Neutral |
| Jul-20-22 | Downgrade | Citigroup | Neutral → Sell |
| Jul-13-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-22 | Downgrade | Stifel | Buy → Hold |
| May-10-22 | Downgrade | Citigroup | Buy → Neutral |
| May-13-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-09-20 | Downgrade | Citigroup | Buy → Neutral |
| Dec-08-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-10-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-30-20 | Initiated | Evercore ISI | Outperform |
| Jun-15-20 | Initiated | H.C. Wainwright | Buy |
| Apr-23-20 | Upgrade | Citigroup | Neutral → Buy |
| Nov-08-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-27-19 | Downgrade | Goldman | Neutral → Sell |
| Sep-16-19 | Downgrade | Jefferies | Buy → Hold |
| Jun-04-19 | Upgrade | Citigroup | Sell → Neutral |
| May-30-19 | Initiated | ROTH Capital | Buy |
| May-23-19 | Initiated | Stifel | Buy |
| Jan-23-19 | Initiated | Mizuho | Buy |
| Apr-10-18 | Initiated | JP Morgan | Overweight |
| Mar-16-18 | Initiated | Guggenheim | Neutral |
| Mar-05-18 | Reiterated | Jefferies | Buy |
| Feb-28-18 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Feb-15-18 | Downgrade | Citigroup | Neutral → Sell |
| Jan-03-18 | Upgrade | Citigroup | Sell → Neutral |
| Oct-06-17 | Resumed | Goldman | Neutral |
View All
Atara Biotherapeutics Inc Stock (ATRA) Latest News
Atara Biotherapeutics (ATRA) director awarded 24,000 restricted stock units - Stock Titan
Atara Biotherapeutics (NASDAQ: ATRA) director reports 38,320-share common stock holding - Stock Titan
Atara Biotherapeutics appoints Brian Cherry to board By Investing.com - Investing.com Australia
Atara Biotherapeutics Adds Independent Director to Board - TipRanks
Atara Biotherapeutics appoints Brian Cherry to board - Investing.com
New Atara (NASDAQ: ATRA) director and 2026 shareholder vote outcomes - Stock Titan
Atara Biotherapeutics Announces Changes to Its Board of Directors - The Joplin Globe
symbol__ Stock Quote Price and Forecast - CNN
Atara Biotherapeutics (ATRA) director granted 12,000 restricted stock units - Stock Titan
Atara Biotherapeutics (ATRA) director receives 12,000-share RSU grant - Stock Titan
Atara Biotherapeutics (ATRA) awards director 12,000 RSUs and reports fund holdings - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
ATRA: All proposals, including director elections and equity plan amendment, were approved - TradingView
Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Atara Biotherapeutics Inc Annual Shareholders Meeting Transcript - GuruFocus
2026-06-09 | Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:ATRA | Press Release - Stockhouse
(ATRA) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Connect - ACCESS Newswire
2026-06-07 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Connect | NDAQ:ATRA | Press Release - Stockhouse
ATRA stock shoots up 82% in a month: Here's what you should know - MSN
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
2026-06-04 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Stockholders to Learn More About the Investigation | NDAQ:ATRA | Press Release - Stockhouse
Atara Biotherapeutics, Inc. Common Stock (ATRA) Stock Price Today & Analysis - Gotrade
ATRA News | ATARA BIOTHERAPEUTICS INC (NASDAQ:ATRA) - ChartMill
Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Investors to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeuti - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Reach Out - ACCESS Newswire
2026-05-31 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Reach Out | NDAQ:ATRA | Press Release - Stockhouse
Atara Biotherapeutics (ATRA) Drops Over 6% as Stock Nears Critical Support LevelStandard Deviation - newsline.com
How (ATRA) Movements Inform Risk Allocation Models - Stock Traders Daily
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Atara Biotherapeutics, Inc. (ATRA) And Encourages Stockholders to Reach Out - ACCESS Newswire
2026-05-28 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Atara Biotherapeutics, Inc. (ATRA) And Encourages Stockholders to Reach Out | NDAQ:ATRA | Press Release - Stockhouse
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 22, 2026 in Atara Biotherapeutics, Inc. LawsuitATRA - Morningstar
Atara Biotherapeutics (ATRA) Faces Selling Pressure Near Key Resistance ZoneNews Sentiment - newsline.com
ATRA FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026 - New Castle News
Atara Biotherapeutics Analyst Ratings and Price Targets | NASDAQ:ATRA - Benzinga
ATRA DEADLINEFINAL REMINDER: Bronstein, Gewirtz & Grossman LLC Alerts Atara Biotherapeutics, Inc. Investors to Participate in the Class Action Lawsuit Today - ACCESS Newswire
ATRA Deadline: Rosen Law Firm Urges Atara Biotherapeutics, Inc. (NASDAQ: ATRA) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights - New Castle News
Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - Barchart.com
ATRA FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Atara Bi - GuruFocus
ATRA DEADLINE TODAY: ROSEN, A LEADING LAW FIRM, Encourages - GlobeNewswire
ATRA DEADLINE REMINDER: Bronstein, Gewirtz & Grossman LLC Reminds Atara Biotherapeutics, Inc. Investors to Join the Class Action Lawsuit Today - ACCESS Newswire
ATARA DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class ActionATRA - TMX Newsfile
ATRARA (NASDAQ:ATRA) DEADLINE MAY 22nd: Bragar Eagel & - GlobeNewswire
Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain OfficersATRA - PR Newswire
Bronstein, Gewirtz & Grossman LLC Urges Atara - GlobeNewswire
ATRA Stock Shoots Up 82% in a Month: Here's What You Should Know - The Globe and Mail
ATRA EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Atara - GuruFocus
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
ATRA EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026 - PR Newswire
Atara Biotherapeutics, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky Before May 22, 2026 to Discuss Your RightsATRA - PR Newswire
Atara Biotherapeutics Inc Stock (ATRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):